Endothelial function trajectories during anthracycline chemotherapy by baseline cardiovascular risk: a prospective three-time point study

Clicks: 1
ID: 323490
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #259 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background In patients receiving anthracycline therapy, a decline in FMD reflects the development of endothelial dysfunction and may represent an early vascular response preceding myocardial involvement. Nevertheless, whether early FMD changes can reliably predict subsequent asymptomatic left ventricular dysfunction remains an open question. Purpose To evaluate longitudinal changes in FMD according to baseline cardiovascular risk and to explore whether early FMD changes are associated with subsequent asymptomatic cancer-therapy-related cardiac dysfunction (CTRCD) during anthracycline therapy. Methods This prospective analysis included 71 women (mean age 55.4±11.2 years) receiving anthracycline-containing chemotherapy. Patients were stratified into a low-risk group (n=40) and a moderate-to-high-very high risk group (n=31)according to the HFA-ICOS risk assessment. Cardiovascular evolution, monitoring and definition of asymptomatic CTRCD followed the 2022 ESC cardio-oncology recommendations. FMD was measured at baseline (T0), after 4 cycles (T1), and after 8 cycles (T2) using a validated automated FMD analysis. Between-group difference and longitudinal changes in FMD were performed using appropriate non-parametric methods. The association between early FMD change and CTRCD was assessed using logistic regression with adjustment for baseline cardiovascular risk; an additional threshold analysis evaluated the upper quartile of early FMD decrease (≥0.70). Results Cumulative anthracycline dose was 225.0±44.5 mg/m² in the low-risk group and 209.1±45.1 mg/m² in the moderate-to-high-very high risk group. FMD values were consistently higher in the low-risk group than in the moderate-to-high-very high risk group at baseline (11.40% vs 7.80%; p<0.001), after 4 cycles (10.85% vs 7.10%; p<0.001), and after 8 cycles (10.60% vs 6.50%; p<0.001) (Figure 1). A significant decline in FMD over time was observed in both risk groups (p < 0.001). Asymptomatic LV dysfunction after 8 cycles occurred in 19/71 patients (26.7%), with no significant difference between risk groups. Early FMD decline was not associated with the occurrence of asymptomatic CTRCD in univariable analysis OR 1.06(95% CI 0.85-1.32) or after adjustment for baseline cardiovascular risk OR 1.09(95% CI 0.86-1.37). The threshold analysis (Early FMD decrease ≥0.70) also showed no difference in outcome frequency (p=0.699). Conclusions During anthracycline chemotherapy, FMD trajectories differ according to baseline cardiovascular risk, with consistently lower FMD values in patients with moderate-to-high risk. In this cohort, early decline in FMD was not associated with subsequent asymptomatic LV dysfunction, suggesting that endothelial dysfunction, while an early vascular response to chemotherapy, may not be sufficient as a stand-alone predictor of CTRCD.Figure 1
Reference Key
openalex_W7172277619 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Amanova, Z H Tlegenova, S Balmagambetova, G Kurmanalina, I Talipova, G Sultanbekova, K Kubenova, M Baspayeva, S Madinova, Z Bulekova, B Zholdin
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.108
URL
https://doi.org/10.1093/eurheartjsupp/suag097.108
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.